| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| Ab175883-100μg | 100μg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $49.90 |
Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG4SP; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| Product Name | Ixekizumab (anti-CTLA-8) - Primary antibody, specific to IL17A, >95%, high purity, Human IgG4SP |
|---|---|
| Synonyms | CTLA 8 antibody | CTLA-8 antibody | CTLA8 antibody | cytotoxic T lymphocyte associated antigen 8 antibody | Cytotoxic T lymphocyte associated protein 8 antibody | Cytotoxic T lymphocyte associated serine esterase 8 antibody | Cytotoxic T-lymphocyte-associ |
| Specifications & Purity | ExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot |
| Host species | Human |
| Specificity | IL17A |
| Conjugation | Unconjugated |
| Grade | Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Action Type | INHIBITOR |
| Mechanism of action | INHIBITOR of Interleukin 17A inhibitor |
| Product Description | Ixekizumab (anti-CTLA-8) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A (KD<3 pM). Ixekizumab (anti-CTLA-8) directly blocks IL-17A binding to IL-17RA (IL-17A receptor) but does not bind to other IL-17 family members. Ixekizumab (anti-CTLA-8) is used for the research of moderate-to-severe plaque psoriasis. Purity |
| Isotype | Human IgG4SP |
|---|---|
| Light Chain Type | kappa |
| SDS-PAGE | 27.6 kDa (Light Chain) & 51.2 kDa (Heavy Chain), under reducing conditions; 167.7 kDa, under non-reducing conditions. |
| Purification Method | Protein A purified |
| Purity | >95% |
| Form | Liquid |
| Concentration | Lot by Lot |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle. |
| CAS | 1143503-69-8 |
Ixekizumab (anti-CTLA-8) (Ab175883) - ELISA
Immobilized Recombinant Human IL-17A Protein at 0.5 μg/mL can bind Ixekizumab (anti-CTLA-8) (Ab175883) with the EC₅₀ of 33.85 ng/mL.
Ixekizumab (anti-CTLA-8) (Ab175883) - SEC
The purity of Ixekizumab (anti-CTLA-8) (Ab175883) is more than 95% verified by HPLC.
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
 ZJ23F1202008 | Certificate of Analysis | Dec 13, 2023 | Ab175883 |
| ZJ23F1202007 | Certificate of Analysis | Dec 13, 2023 | Ab175883 |
| 1. Ohtsuki M, Morita A, Abe M, Takahashi H, Seko N, Karpov A, Shima T, Papavassilis C, Nakagawa H, ERASURE Study Japanese subgroup. (2014) Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study.. J Dermatol, 41 (12): (1039-46). [PMID:25354738] [10.1021/op500134e] |
| 2. Wright JF, Bennett F, Li B, Brooks J, Luxenberg DP, Whitters MJ, Tomkinson KN, Fitz LJ, Wolfman NM, Collins M et al.. (2008) The human IL-17F/IL-17A heterodimeric cytokine signals through the IL-17RA/IL-17RC receptor complex.. J Immunol, 181 (4): (2799-805). [PMID:18684971] [10.1021/op500134e] |
| 3. Yao, Z Z and 6 more authors.. (1995) Human IL-17: a novel cytokine derived from T cells.. Journal of immunology (Baltimore, Md. : 1950), (15): [PMID:7499828] |
| 4. Fossiez, F F and 16 more authors.. (1996) T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines.. The Journal of experimental medicine, (1): [PMID:8676080] |
| 5. Wright, Jill F JF and 12 more authors.. (2007) Identification of an interleukin 17F/17A heterodimer in activated human CD4+ T cells.. The Journal of biological chemistry, (4): [PMID:17355969] |
| 6. Kuestner, Rolf E RE and 27 more authors.. (2007) Identification of the IL-17 receptor related molecule IL-17RC as the receptor for IL-17F.. Journal of immunology (Baltimore, Md. : 1950), (15): [PMID:17911633] |
| 7. Liu, Caini C and 9 more authors.. (2009) Act1, a U-box E3 ubiquitin ligase for IL-17 signaling.. Science signaling, (13): [PMID:19825828] |
| 8. Gerhardt, Stefan S and 22 more authors.. (2009) Structure of IL-17A in complex with a potent, fully human neutralizing antibody.. Journal of molecular biology, (18): [PMID:19835883] |
| 9. Puel, Anne A and 23 more authors.. (2011) Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity.. Science (New York, N.Y.), (1): [PMID:21350122] |
| 10. Boisson, Bertrand B and 12 more authors.. (2013) An ACT1 mutation selectively abolishes interleukin-17 responses in humans with chronic mucocutaneous candidiasis.. Immunity, (17): [PMID:24120361] |
| 11. Acharya, Dhiraj D and 11 more authors.. (2017) Interleukin-17A Promotes CD8+ T Cell Cytotoxicity To Facilitate West Nile Virus Clearance.. Journal of virology, (1): [PMID:27795421] |
| 12. Goepfert, Arnaud A, Lehmann, Sylvie S, Wirth, Emmanuelle E and Rondeau, Jean-Michel JM.. (2017) The human IL-17A/F heterodimer: a two-faced cytokine with unique receptor recognition properties.. Scientific reports, (21): [PMID:28827714] |
| 13. Goepfert, Arnaud; Lehmann, Sylvie; Blank, Jutta; Kolbinger, Frank and Rondeau, Jean-Michel.. (2020) Structural Analysis Reveals that the Cytokine IL-17F Forms a Homodimeric Complex with Receptor IL-17RC to Drive IL-17RA-Independent Signaling.. Immunity, (17): [PMID:32187518] |
